ESK-001-019
12 evidence topics · 1 source
Objective
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2024-06-21” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2024-08-31” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2024-08-31” (opens the source at this quote in a new tab)
“First Submitted 2025-12-10” (opens the source at this quote in a new tab)
“First Posted 2026-01-30” (opens the source at this quote in a new tab)
Site in Daytona Beach, Florida, in the ClinicalTrials.gov record
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-01-30” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-019” |
| Conditions | “Healthy Volunteer” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |
Four treatment sequences, blinding, and central electrocardiogram reading
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using placebo-adjusted change in QTcF as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- The study is known only from its ClinicalTrials.gov record, which reads “No Results Posted”; the report holds no QTcF, ECG, pharmacokinetic, or safety result.
- The record was first submitted on 2025-12-10, after the actual study completion date of 2024-08-31.
- The record describes the therapeutic and supratherapeutic arms each as one oral dose of ESK-001 without stating the dose.
- The study gave single doses to 52 healthy participants aged 18 to 55 years at one site, with the moxifloxacin positive control given open label.